| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0597f9c318d2aeca86db94711c516383 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-75
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate |
2018-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c27a815967e76996248fd819a77fa441
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9d312c39d5ef29e7ef571998ec6e56f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e29d0dd9e7783df16703f472d7d79b4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f69f51e0643e91b5a32b89c85d22e44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_245589b0bc8dcc3c89c69c8c12b7a0d8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec9e6147a1821f8558b25901e90377f7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f685a9ab2be2681a5ff33077608d7b7 |
| publicationDate |
2021-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11186636-B2 |
| titleOfInvention |
Anti-human TREM2 antibodies and uses thereof |
| abstract |
The present invention relates to antigen binding proteins, such as monoclonal antibodies, that specifically bind to and activate human triggering receptor expressed on myeloid cells-2 (TREM2) and pharmaceutical compositions comprising such antigen binding proteins. The agonist antigen binding proteins (e.g. antibodies) of the invention are capable of activating TREM2/DAP12 signaling in myeloid cells in the absence of Fc-mediated cross-linking of the antigen binding proteins. Methods of treating or preventing conditions associated with TREM2 loss of function, such as Alzheimer's disease and multiple sclerosis, using the antigen binding proteins are also described. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023192288-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023192282-A1 |
| priorityDate |
2017-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |